Tuesday, May 13, 2025
  • Login
No Result
View All Result
ForexTV
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates
No Result
View All Result
ForexTV
No Result
View All Result
ADVERTISEMENTS
club Felene

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

by GlobeNewswire
April 22, 2024
in Top News
Reading Time: 10 mins read

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline.

“2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “With respect to our DFC platform, we continue to generate and present compelling data from our oncology programs as well as our CD388 influenza program partnered with Janssen. We have multiple key catalysts expected this year, including the filing of an Investigational New Drug Application (IND) in mid-2024 for CBO421, a potential best-in-class inhibitor of CD73. We recently presented promising new data on CD73/PD-1 multispecific DFC, CCR5-targeting DFC and CBO421 at the American Association for Cancer Research (AACR) Annual Meeting.”

Dr. Stein continued, “Most recently, REZZAYO was approved in the European Union (EU) and United Kingdom (UK) for the treatment of invasive candidiasis in adults, earning milestone payments of approximately $11.1 million and $2.8 million, respectively. In addition, enrollment was completed in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis, bringing us one step closer to making this important drug available to an even broader global patient population.”

Recent Corporate Highlights

  • Presented at AACR Annual Meeting 2024: In April 2024, Cidara presented promising new data on novel Cloudbreak DFC candidates at the AACR Annual Meeting. The Company delivered four poster presentations highlighting the data on the Company’s multispecific CD73/PD-1 DFC, its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • Presented at IDWeek 2023: In October 2023, Cidara presented new preclinical and clinical data on Novel Cloudbreak Influenza Drug-Fc Conjugate CD388 at IDWeek 2023.
  • Presented at ESMO Immuno-Oncology Annual Congress: In December 2023, Cidara presented new preclinical data on its novel Cloudbreak, multi-specific CD73/PD-1 targeting DFC candidate at the ESMO Immuno-Oncology (IO) Annual Congress. The Company also presented new preclinical data on Cloudbreak CBO421, its first-in-class CD73-targeting DFC.
  • Presented at SITC’s 38th Annual Meeting: In November 2023, Cidara presented new preclinical data on Cloudbreak CBO421 at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting.
  • Received EU and UK approval for REZZAYO for the treatment of invasive candidiasis in adults: In December 2023 and January 2024, Cidara and Mundipharma announced REZZAYO had been approved in the EU and UK, respectively, for the treatment of invasive candidiasis in adults. Cidara received a milestone payment of approximately $11.1 million from Mundipharma in February 2024 for the EU approval of rezafungin and received a milestone payment of approximately $2.8 million from Mundipharma in April 2024 for the UK approval of rezafungin, in accordance with the terms of the Collaboration and License Agreement, dated September 3, 2019, by and between the Company and Mundipharma.
  • Completed enrollment in the Phase 3 ReSTORE trial of rezafungin in China: In December 2023, Cidara and Mundipharma announced the completion of enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis. The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current standard of care, to treat patients with candidemia and/or invasive candidiasis. Data from this study are expected in the second quarter of 2024.
  • Named San Diego Metro Area Top Workplace: In November 2023, Cidara was named a Top Workplace by The San Diego Union-Tribune for the sixth year, ranking among the top 100 companies.

Fourth Quarter and Full Year 2023 Financial Results

  • Revenue totaled $17.6 million and $63.9 million for the three months and full year ended December 31, 2023, respectively, compared with $10.2 million and $64.4 million for the same periods in 2022.

    Revenue for the year ended December 31, 2023 related to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $16.4 million, $23.3 million and $19.7 million, respectively, $0.2 million in royalty revenue recognized following initiation of the commercial launch of REZZAYO in the U.S. on July 31, 2023, as well as product revenue of $4.3 million related to shipments of REZZAYO naked vials to Melinta and Mundipharma.

    Revenue for the year ended December 31, 2022 included $25.9 million of revenue recognized upon transfer of an intellectual property license to Melinta in August 2022. The remaining revenue for the year ended December 31, 2022 related to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $14.3 million, $23.5 million and $0.8 million, respectively.

  • Cash and cash equivalents totaled $35.8 million as of December 31, 2023, compared with $32.7 million as of December 31, 2022.
  • As of December 31, 2023, Cidara had 90,601,999 shares of common stock outstanding, and 2,104,472 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 21,044,720 shares of common stock.
  • Cost of product revenue was $1.5 million for the year ended December 31, 2023 and primarily consisted of direct material costs, third-party manufacturing costs and indirect overhead costs associated with the manufacture, quality assessment and delivery of REZZAYO naked vials shipped to Melinta and Mundipharma. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.
  • Research and development expenses were $14.7 million and $68.5 million for the three months and full year ended December 31, 2023, respectively, compared to $20.1 million and $77.4 million for the same periods in 2022. The decrease in research and development expenses for the full year ended December 31, 2023 compared to the full year ended December 31, 2022 is primarily due to lower clinical expenses associated with the rezafungin clinical trials and lower consulting and personnel costs, offset by higher clinical expenses associated with our Cloudbreak platform.
  • Selling, general and administrative (SG&A) expenses were $5.4 million and $18.3 million for the three months and full year ended December 31, 2023, respectively, compared to $3.6 million and $20.5 million for the same periods in 2022. The decrease in SG&A expenses for the full year ended December 31, 2023 compared to the full year ended December 31, 2022 is primarily due to lower consulting, personnel and legal costs, and lower amortization of contract costs related to obtaining the Melinta License Agreement, offset by higher selling expenses related to REZZAYO.
  • Net loss for the three months ended December 31, 2023 was $3.2 million, compared to a net loss of $13.6 million for the three months ended December 31, 2022. Net loss for the full year ended December 31, 2023 was $22.9 million, compared to a net loss of $33.6 million for the year ended December 31, 2022.

Restatement of Consolidated Financial Statements

The financial results included herein and the financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) have been restated to account for indirect taxes that led to understatements of accrued liabilities and operating expenses, as more fully described in our Current Report on Form 8-K filed with the United States (U.S.) Securities and Exchange Commission (the SEC) on April 16, 2024 and in the Form 10-K.

About Cidara Therapeutics

Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA and EC approval for REZZAYO® (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether the advantages of the CD388 program for influenza will continue to translate to our Cloudbreak oncology DFC programs, whether we will file an IND in mid-2024 for CBO421, whether we will achieve future royalties and milestones under both our Melinta and Mundipharma licensing agreements, whether we will receive additional milestones, and any royalties, from our collaboration agreement with Janssen, and the timing of data from the Phase 3 ReSTORE trial of rezafungin. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, delays in action by regulatory authorities, and other obstacles on the enrollment of patients or other aspects of rezafungin, CD388, or other DFC development. These and other risks are identified under the caption “Risk Factors” in Cidara’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and other filings subsequently made with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT: 
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT: 
Veronica Eames
LifeSci Communications
(646) 970-4682
veames@lifescicomms.com

CIDARA THERAPEUTICS, INC.

Condensed Consolidated Statements of Operations

 
 Three months ended
December 31,
 Year ended
December 31,
(In thousands, except share and per share data) 2023   2022   2023   2022 
   (As Restated)   (As Restated)
Revenues:(Unaudited) (Unaudited)    
Collaboration revenue$14,716  $10,219  $59,570  $64,448 
Product revenue 2,867   —   4,335   — 
Total revenues 17,583   10,219   63,905   64,448 
Operating expenses:       
Cost of product revenue 1,136   —   1,523   — 
Research and development 14,718   20,111   68,532   77,405 
Selling, general and administrative 5,405   3,595   18,333   20,546 
Total operating expenses 21,259   23,706   88,388   97,951 
Loss from operations (3,676)  (13,487)  (24,483)  (33,503)
Other income, net:       
Interest income, net 527   162   1,995   191 
Total other income, net 527   162   1,995   191 
Loss before income tax expense (3,149)  (13,325)  (22,488)  (33,312)
Income tax expense (64)  (272)  (443)  (272)
Net loss and comprehensive loss$(3,213) $(13,597) $(22,931) $(33,584)
Basic and diluted net loss per common share$(0.04) $(0.19) $(0.26) $(0.48)
Shares used to compute basic and diluted net loss per common share 90,504,622   71,895,890   87,427,439   69,857,698 

 
Condensed Consolidated Balance Sheet Data
 
 December 31,
  2023   2022 
(In thousands)  (As Restated)
Cash and cash equivalents$35,778  $32,731 
Total assets 67,030   47,487 
Total liabilities 75,240   61,925 
Total stockholders’ deficit (8,210)  (14,438)

 

  • Author
  • Recent Posts
GlobeNewswire
GlobeNewswire
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
GlobeNewswire
Latest posts by GlobeNewswire (see all)
  • Cleanfarms Celebrates 15 Years of Agricultural Sustainability Leadership - May 13, 2025
  • High Wire Networks Reports First Quarter Earnings Revenue Growth and Operating Margin Increases - May 13, 2025
  • Freehold Royalties Announces First Quarter 2025 Results - May 13, 2025
ADVERTISEMENTS
ForexTV Digital Marketing

Related Posts

Cleanfarms Celebrates 15 Years of Agricultural Sustainability Leadership

by GlobeNewswire
May 13, 2025
0

Pesticide and fertilizer containers under 23L Pesticide and fertilizer containers under 23L, prepared for drop-off at a collection site to...

High Wire Networks Reports First Quarter Earnings Revenue Growth and Operating Margin Increases

by GlobeNewswire
May 13, 2025
0

BATAVIA, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- High Wire Networks, Inc. (OTCQB: HWNI), a leading global provider of managed cybersecurity,...

Freehold Royalties Announces First Quarter 2025 Results

by GlobeNewswire
May 13, 2025
0

CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results...

Peyto Reports First Quarter 2025 Results

by GlobeNewswire
May 13, 2025
0

CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased...

Condor Announces 2025 First Quarter Results and Purchase of Its First LNG Facility

by GlobeNewswire
May 13, 2025
0

CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based, internationally...

Optiva Inc. Reports First Quarter 2025 Financial Results

by GlobeNewswire
May 13, 2025
0

All amounts are stated in United States dollars unless otherwise indicated Revenue of $11.6 millionTotal Contract Value (“TCV”)(1) bookings of...

Next Post

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages World Acceptance Corporation Investors to Inquire About Securities Class Action Investigation – WRLD

Please login to join discussion
ADVERTISEMENTS

Latest Posts

  • Cleanfarms Celebrates 15 Years of Agricultural Sustainability Leadership May 13, 2025
  • High Wire Networks Reports First Quarter Earnings Revenue Growth and Operating Margin Increases May 13, 2025
  • Freehold Royalties Announces First Quarter 2025 Results May 13, 2025
  • Peyto Reports First Quarter 2025 Results May 13, 2025
  • Condor Announces 2025 First Quarter Results and Purchase of Its First LNG Facility May 13, 2025
  • About Us
  • Advertise
  • Careers
  • Contact
Privacy Policy / Terms and Conditions

© 2024 ForexTV.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Cookie Policy
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
No Result
View All Result
  • News
    • Top Corporate News
    • Lifestyle
    • Technology
    • Financial Markets News
  • Small Business
    • Digital Marketing Blog
    • Small Business Best Practices
    • Small Business Strategy
      • Sales Strategies
      • Marketing Strategies
  • Business Finance
    • Small Business-Lending Trends
    • Debt Service Coverage Ratio (DSCR)
    • Business Credit
      • Business Credit Blog
      • Business Loans
      • Merchant Cash Advances
      • Business Line of Credit
      • What is Alternative Business Lending?
    • Resources
      • Debt Service Coverage Ratio (DSCR) Calculator
  • Currency Focus
    • Crypto Focus
      • Bitcoin (BTC)
      • Ethereum (ETH)
      • Tether
      • BNB
      • Cardano (Ada)
      • Ripple (XRP)
      • Solana (SOL)
      • Dogecoin (DOGE)
      • Polkadot (DOT)
      • Tron (TRX)
      • Shiba Inu (SHIB)
      • Litecoin (LTC)
    • EURO (EUR)
    • Japanese Yen (JPY)
    • Great British Pound (GBP)
    • Swiss Franc (CHF)
    • New Zealand Dollar (NZD)
    • Canadian Dollar (CAD)
    • Australian Dollar (AUD)
  • Resources
    • Economic Calendar
    • Trader Education
      • Candlestick Pattern Intro
    • Live Forex Rates/Charts
      • Live Rates
      • Live Charts
    • Forex Trader Tools
      • Pivot Point Calculator
      • Currency Converter
      • Global Statistic Resources
    • Trading Terms
      • Forex Glossary
      • Glossary of Retirement Industry Terms
    • CPI Tools
      • CPI Inflation Calculator
      • CPI Average Price Calculator
  • Marketing Services
    • Digital Marketing Services
    • Digital Marketing Consulting
    • Search Engine Optimization (SEO)
    • Online Content Marketing
    • Digital Marketing Blog
    • Inbound Marketing Services
    • Email Marketing
    • Digital Marketing Rates

© 2024 ForexTV.com